When women are diagnosed with ductal carcinoma in situ (DCIS)—an early, non invasive form of breast cancer—the natural question is, “What’s the right treatment for me?” For decades, the answer has been shaped by broad categories. Based on visible features such as tumor size, grade, surgical margins and hormone receptor status, doctors would place patients into generic “low risk” or “higher risk” categories. But the treatment advised would be the same; surgery followed by radiation, even for those whose tumors looked relatively harmless. Radiation, however, isn’t a one-size-fits-all safeguard. Two women with tumors that look identical on paper can face very different outcomes—one might gain real protection against recurrence, while the other might endure side effects with little or no added benefit. And traditional tools couldn’t reliably distinguish between them. PreludeDx™ created DCISionRT® to change that. Instead of relying solely on how a tumor appears based on clinical and pathologic factors alone, the test integrates clinical and pathologic factors with the tumor’s underlying biology—the molecular signals that dictate its behavior. From this, it generates a Decision Score™ that provides two answers at once: a woman’s 10-year risk of recurrence, and the likelihood that radiation will significantly reduce that risk. “Our test provides doctors the clarity to make a better and more informed treatment decision and patients the confidence that their treatment is the right one for them and not a one-size-fits-all approach,” says Troy Bremer, Chief Scientific Officer. DCISionRT assesses seven key protein biomarkers within the tumor. These biomarkers act like fingerprints, revealing how fast the tumor grows, how sensitive it is to hormones, how well it repairs itself under stress, and how it regulates its cell cycle. The biological signals are combined with standard clinical data, such as age, tumor size and surgical margins, and then entered into PreludeDx’s proprietary algorithm. The algorithm then generates a score on a 10-point scale, where higher numbers indicate a higher recurrence risk and benefit from radiation therapy.   The Decision Score categorizes each patient into one of three categories—low, elevated and residual risk—with very different implications for risk and treatment..

A Japanese-American man grew up believing he came from a proud Samurai bloodline. That was the story passed down in his family, shaped by heritage and rooted in honor. But when he opened his CRI Genetics report, the narrative took a surprising turn. Only 58 percent of his DNA was of Japanese descent. The rest pointed to Chinese, Vietnamese, and even Peruvian ancestry. What began as a search for confirmation became a journey through forgotten trade routes, cultural intersections, and ancestral revelations. His sense of identity expanded beyond borders. Complex global stories became deeply personal. At CRI Genetics, stories like this are common. Customers set out to confirm one story and end up unlocking hidden truths that reshape their identity. This kind of rediscovery is exactly what CRI Genetics was built to make possible while putting the customer at the center of everything it does. The goal is not just to scratch the surface of your identity, but to deliver deeper self-knowledge than you can get anywhere else. The company blends scientific precision with emotional insight. They turn strands of genetic data into experiences that help people understand their ancestry, their health, and their human potential. “We didn’t set out to build another ancestry company. We wanted to create a bridge between rigorous science and real people, between raw data and life-changing insight, so that every person who opens one of our kits walks away feeling seen,” says Alex Mulyar, CEO. Personalized from the Start At CRI Genetics, ancestry is more than just tracking family names or geographical roots. It’s a comprehensive, multi-layered journey. Most DNA companies stop at five to eight generations of ancestry. CRI Genetics pushes the boundaries of genetic science. Their reports trace your ancestry back up to 50 generations into your family’s past, deep into the Renaissance era. One simple cheek swab could put six centuries of family history in your hands..

ERA Health Research is a physician-led, national clinical research site network specializing in advancing high-impact studies with speed, precision, and proven performance. Founded by emergency physicians in Kirkland, Washington—one of the first hospitals impacted by COVID-19—ERA quickly built a reputation for excellence by running a pioneering monoclonal antibody infusion research study and quickly expanding into complex, high-demand therapeutic areas. To date, ERA has participated in approximately 150 clinical studies across multiple therapeutic areas, demonstrating depth of experience and operational consistency that sponsors and CROs depend on. These studies span blood manipulation therapies, neurology and cognitive decline, and AI-powered cardiac imaging, along with established strengths in diabetes, obesity, GLP-1 receptor agonists, and hospital-based point-of-care research. Sponsors and CROs rely on ERA to execute even the most complex protocols, including helping to support those seeking 510(k) approval, all thanks to its full-time principal investigators and highly trained nurse coordinators who combine deep clinical expertise with patient-focused engagement. ERA’s model is unique: the organization integrates Registered Nurses (RNs) directly into its recruiting team, leveraging their medical expertise to carefully identify and screen the most appropriate participants for each study. These RNs work alongside physicians to assess inclusion and exclusion criteria, ensure safety, and optimize participant suitability—improving data integrity, patient outcomes, and overall study performance. ERA excels at identifying and recruiting a broad range of study participants, ensuring strong representation across all ethnicities and backgrounds. This commitment to inclusion enhances data diversity and relevance, producing more accurate and representative results that better reflect real-world populations. Sponsors recognize ERA’s ability to meet diversity goals while maintaining precision, compliance, and patient care excellence. This physician-led structure differentiates ERA from traditional research sites that depend on part- time or third-party staff. Full-time investigators ensure that trials stay on schedule, deviations remain under 3 percent, and queries are answered within 48 hours. The combination of physician leadership, skilled nurse coordinators, RN-driven recruiting practices, and inclusive enrollment strategies drives patient retention above 99 percent and enables ERA to consistently achieve top national enrollment rankings for both hospital-based point-of-care studies and complex pharmaceutical/device trials. Built on transparency and selectivity, ERA only undertakes trials it can execute successfully, prioritizing quality over quantity. This approach creates consistently high-value outcomes, extending sponsor relationships and often securing additional or larger studies. Many patients return for multiple trials—some completing a dozen—reflecting deep satisfaction and trust..

High-quality and representative clinical trial data has never been more critical for sponsors and contract research organizations (CROs), as they advance new treatments. At Peters Medical Research (PMR), diversity and scientific precision go hand in hand—powering high-integrity results across Phase II–IV clinical studies. With more than two decades of success completing nearly 300 clinical trials, it has earned a reputation for being not only a top enroller but also a full-spectrum top performer. As an affiliate of Bethany Medical, the largest independent healthcare provider in the Triad region, PMR taps directly into a database of more than 250,000 patients across 16 locations and 14 medical specialties. This network affords broad access to a diverse population that reflects the real-world diversity of our local communities. The site employs innovative recruitment strategies, strong community engagement and a commitment to underserved populations to ensure inclusivity. “We partner with patients today to deliver the treatments of tomorrow, driving medical research forward with purpose, precision and speed,” says Dr. Lenin Peters, founder and CEO. Dr. Peters, a gastroenterologist with hands-on experience in initial proton pump inhibitor studies, recognized early on that clinical trials often lacked diversity, limiting the applicability of their results. This insight became the catalyst for establishing PMR. Since PMR began over 20 year ago with a focus on GI disorders as their primary therapeutic area, the organization has since expanded to support clinical trials across myriad therapeutic areas. PMR’s reputation for rapid, reliable enrollment is backed by measurable success. In a recent lung cancer study, the site enrolled 729 participants in just 12 months. A complex migraine trial reached its target of nearly two dozen participants in only one month, and an obesity study achieved full randomization in under six weeks—clear evidence of PMR’s operational excellence and recruitment expertise. Committed to broadening access to clinical research, PMR continuously refines its recruitment strategies to reach underserved and low-income communities. Recognizing that trial participation can feel intimidating for those unfamiliar with medical research, the organization places strong emphasis on health literacy and community education. Through Bethany Medical Clinic, PMR provides accessible educational materials and resources that empower patients to make informed decisions about participation. By integrating marketing, branding, and innovative educational approaches, PMR builds awareness, fosters trust, and ensures that research opportunities are inclusive and approachable for all..